About ProkariumProkarium’s vision is that all protein vaccines can be delivered orally. Our Vaxonella® platform enables this, while also being a strong stimulator of all arms of immunity, as well as reducing costs and time for vaccine manufacture. Prokarium is based in Keele and London, UK.
CEO: Ted Fjällman
CSO: Rocky Cranenburgh
CFO: Peter Coleman
Please click here for clinical trial information.
Tweets by Prokarium
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.